These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 628014)

  • 1. Enhancement of growth of allogeneic mouse tumor by the IgG1 fraction of alloantibody preparations.
    Harris TN; Harris S; Henri EM; Farber MB
    J Natl Cancer Inst; 1978 Jan; 60(1):167-72. PubMed ID: 628014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussion paper: effect on IgG1 class alloantibody on retention of skin allografts and on tumor growth in the mouse.
    Harris TN; Harris S
    Ann N Y Acad Sci; 1976; 277(00):700-5. PubMed ID: 793488
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative studies on tumor enhancement in mice. I. Enhancement of sarcoma I induced by IgM, IgG1, and IgG2.
    Rubinstein P; Decary F; Streun EW
    J Exp Med; 1974 Aug; 140(2):591-6. PubMed ID: 4846488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
    Burton RC; Warner NL
    J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated suppression of tumor growth. III. Molecular assay of murine IgG1 alloantibody required to cause tumor suppression in vivo.
    Johnson RJ; Pasternack GR; Drysdale BE; Shin HS
    J Immunol; 1977 Feb; 118(2):498-504. PubMed ID: 839068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Various effects of alloantibody-containing globulins on the time of retention of skin allografts in the mouse.
    Harris TN; Harris S; Bocchieri MH; Farber MB; Ogburn CA
    Transplantation; 1972 Oct; 14(4):495-500. PubMed ID: 4566165
    [No Abstract]   [Full Text] [Related]  

  • 9. A preparation of Fc fragment of normal mouse IgG1 for production of rabbit anti mouse IgG1 serum.
    Harris TN; Harris S; Henri EM
    J Immunol Methods; 1975 Sep; 8(3):203-12. PubMed ID: 810516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic markers of V domain of mouse MOPC 21 IgG1 L chain. The conformational basis of VL domain markers and content of MOPC 21 VL-like immunoglobulins in sera of inbred mouse strains.
    Rokhlin OV; Petrosyan MN; Ibraghimov AR; Vengerova TI; Bogachova GT
    Eur J Immunol; 1983 May; 13(5):397-403. PubMed ID: 6189726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive immunity to murine plasmacytoma by rabbit antiidiotypic antibody to myeloma protein.
    Chen Y; Yakulis V; Heller P
    Proc Soc Exp Biol Med; 1976 Jan; 151(1):121-5. PubMed ID: 1250837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of cell-surface antigenicity of the mouse plasmacytoma. II. Lack of correlation between synthesis of myeloma protein and alteration of surface antigen.
    Ohno S; Natsu-ume-Sakai S; Migita S
    J Natl Cancer Inst; 1977 Feb; 58(2):229-37. PubMed ID: 833874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.
    Rashid A; Auchincloss H; Sharon J
    J Immunol; 1992 Mar; 148(5):1382-8. PubMed ID: 1538121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ia versus K/D antigens in immunological enhancement of tumour allografts. II. Studies with alloimmune sera prepared in recombinant strains.
    Duc HT; Kinsky RG; Voisin GA
    Ann Immunol (Paris); 1979; 130C(3):461-74. PubMed ID: 475347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-mouse IgG on some complement-requiring alloantibodies of the mouse.
    Harris TN; Harris S
    J Immunol; 1972 Nov; 109(5):1096-108. PubMed ID: 4627933
    [No Abstract]   [Full Text] [Related]  

  • 19. Similar activities of IgG1 and IgG2 alloantibodies in enhancement of mouse skin grafts and in opsonization.
    Lems SP; Rijke-Schilder TP; Capel PJ; Koene RA
    Transplantation; 1984 Mar; 37(3):291-6. PubMed ID: 6701959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
    Cruse JM; Whitten HD; Lewis GK; Watson ES
    Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.